Published in Cell, a large international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors’ genes and proteins.
Despite decades of study, pancreatic cancer has remained a grim diagnosis, explains study co-author Ralph Hruban, M.D., director of the Sol Goldman Pancreatic Cancer Research Center and professor of pathology at the Johns Hopkins University School of Medicine. Because of its lack of symptoms and dearth of reliable and effective methods for screening and early detection, the vast majority of patients are diagnosed at a late stage when surgery isn’t possible, leading to an extremely poor prognosis. The five-year overall survival rate is less than 10%, says Hruban, and the median survival in patients with metastatic disease is less than 12 months.
Although numerous studies have examined the genes of pancreatic tumors and identified several mutations linked to this disease, adds Zhang, these mutations cannot be targeted with drug therapies. In addition, these tumors don’t attract a significant response from the immune system, so immunotherapies have not been broadly effective.
They compared 140 tumor samples with 67 samples of normal adjacent pancreatic tissue from the same patients, and with nine samples of pancreatic tissue from patients who did not have cancer. The team looked at the whole genome, DNA coding sequences, modifications to DNA that turn certain genes on or off, messenger RNA molecules to which the information in the DNA is transferred, and micro RNAs that regulate gene expression. They took an accounting of proteins produced in pancreatic cancer cells, including various modifications to these proteins, such as adding phosphate groups or sugar molecules that can change their function.Their findings, published online Sept. 16 in Cell, could offer hope to patients with this deadly disease.
The team confirmed that pancreatic tumors are more likely to have mutations in several genes identified in previous studies, including KRAS, TP53, CDKN2A and SMAD4. In addition, they identified 222 proteins with at least a twofold increase in abundance between pancreatic cancerous cells and normal cells; nearly 5,000 sites in these proteins with increased phosphorylation abundance patterns; and more than 1,700 sites with an increase in attached carbohydrates, or glycosylation.
Several of these glycosylated proteins are secreted from pancreatic cancer cells, Zhang says, suggesting they could potentially be captured in the blood for early diagnosis. In addition, PAK1 and PAK2 — two specialized proteins, called kinases, that place phosphate groups onto other proteins — that are dysregulated in pancreatic cancer could offer previously unrecognized targets to treat this disease. There are several small molecule inhibitors targeting PAK1, offering a potential path toward treating pancreatic tumors, which are still under investigation. Other protein differences between the cancer cells and normal tissue appear to be roadblocks that stymie immune system attack, adds Zhang, suggesting new ways to improve immune response to these tumors.
